StartseiteMCPWorkbenchSkills
StartseiteWorkbenchBenachrichtigungenMein Bereich
Huagongshe Open Project：[email protected]KI-Anbindung: llms.txt · MCP-AnleitungDatenschutz · Nutzungsbedingungen · Supportv1.7.8
Zurück
HuagongsheHuagongshe Chemie-Druckbericht · Nur für Forschungszwecke
HCID 5322Erstellt: 5. November 2026

Sulfacytine

Cl 636 · CI-636 · Renoquid · Nsc356717 · Sulfacitinum · N-Sulfanilyl-L-ethylcytosine · 1-Ethyl-N-sulfanilylcytosine · 4-amino-N-(1-ethyl-2-oxopyrimidin-4-yl)benzenesulfonamide

https://huagongshe.com/de/chemical/5322

Molekülstruktur von Sulfacytine

Identifikatoren & physikalische Daten

CAS No.1401-49-6
SummenformelC12H14N4O3S
Durchschnittliche Molmasse294,33 g/mol
Monoisotopische Masse294,07866149 g/mol
SMILESCCn1ccc(NS(=O)(=O)c2ccc(N)cc2)nc1=O
InChIKeySIBQAECNSSQUOD-UHFFFAOYSA-N
PubChem CID5322
ChEMBLCHEMBL1201056
ChEBICHEBI:135230
DTXSIDDTXSID6023606

Chemische & physikalische Eigenschaften

XLogP0,1
Polarare Oberfläche (TPSA)113
H-Brücken-Donoren2
H-Brücken-Akzeptoren4
Frei drehbare Bindungen4
Schwere Atome20
Formalladung0
Komplexität527
ArzneimittelPharmaceuticals -> AntibioticsPharmaceuticals -> Listed in ZINC15
LogP (Verteilungskoeffizient)-0.2
Color/FormCrystals from butyl alcohol, methanolCrystalline
Löslichkeit175 mg sol in 100 mL buffer at pH 5 at 37 °CInsoluble in watersoluble in alkaliSolubility increases with increasing pH.4.68e-01 g/L
Human DrugsFDA approved drugs -> Active ingredient
Schmelzpunkt166.5-168 °CMP: 104 °C /Monohydrate/166.5 °C166.5-168°mp 104°
Physical DescriptionSolid
Dissociation ConstantspK'= 6.9 /as per source/
Siedepunkt496.8±47.0 °C(Predicted)
Dichte1.45±0.1 g/cm3(Predicted)
pKa (Säurekonstante)6.9(at 25℃)
AggregatzustandSolid
FarbeWhite to off-white

Sicherheit & Vorschriften

FDA-AnforderungenThe Approved Drug Products with Therapeutic Equivalence Evaluations List identifies discontinued drug products. Sulfacytine is included on this list.
Special ReportsBriggs GG et alDrugs Preg Lactation 324-377 1984. Drugs in pregnancy and lactation: A reference guide to fetal and neonatal risk (drugs S-Z).
EntsorgungsverfahrenSRP: At the time of review, criteria for land treatment or burial (sanitary landfill) disposal practices are subject to significant revision. Prior to implementing land disposal of waste residue (including waste sludge), consult with environmental regulatory agencies for guidance on acceptable disposal practices.
WechselwirkungenThese medications /coumarin- or indandione-derivative anticoagulantshydantoin anticonvulsants or oral antidiabetic agents/ may be displaced from protein binding sites and/or their metabolism may be inhibited by some sulfonamides, resulting in increased or prolonged effects and/or toxicitydosage adjustments may be necessary during and after sulfonamide therapy. /Sulfonamides/Concurrent use of bone marrow depressants with sulfonamides may increase the leukopenic and/or thrombocytopenic effectsif concurrent use is required, close observation for myelotoxic effects should be considered. /Sulfonamides/Concurrent long-term use of sulfonamides /with estrogen-containing, oral contraceptives/ may result in increased incidence of breakthrough bleeding and pregnancy. /Sulfonamides/Concurrent use /of cyclosporine/ with sulfonamides may increase the metabolism of cyclosporine, resulting in decreased plasma concentration and potential transplant rejection, and additive nephrotoxicityplasma cyclosporine concentrations and renal function should be monitored. /Sulfonamides/For more Interactions (Complete) data for SULFACYTINE (13 total), please visit the HSDB record page.
Milk ConcentrationsSulfonamides are distributed into milk. /Sulfonamides/
Human Toxicity Excerpts/SIGNS AND SYMPTOMS/ Sulfacytine...is capable of causing any of the toxic manifestations produced by the sulfonamides, including serious reactions like kernicterus or Stevens-Johnson syndrome... Common adverse reactions associated with sulfacytine therapy are headache, GI disturbances, and allergic rash. ...Risk of crystalluria /is/ minimal...

Anwendungen & Verwendung

Verwenden

Sulfacytine is a soluble short-acting sulfonamide. Sulfacytine is used as an oral antibiotic.

Non-Human Toxicity Excerpts/LABORATORY ANIMALS: Developmental or Reproductive Toxicity/ Teratogenic studies in rats and rabbits have revealed no evidence of impaired fertility or harm to the fetus following use of sulfacytine.
Populations at Special RiskAcute hemolytic anemia may occur during the first week of therapy as a result of sensitization or glucose-6-phosphate dehydrogenase (G-6-PD) deficiency. This reaction may also occur in the fetus or premature infant in whom G-6-PD is normally deficient. /Sulfonamides/Patients with acquired immunodeficiency syndrome (AIDS) may have a greater incidence of side/adverse effects, especially rash, fever, and leukopenia, than do non-AIDS patients. /Sulfonamides/Except as concurrent adjunctive therapy with pyrimethamine in the treatment of congenital toxoplasmosis, use of sulfonamides is contraindicated in infants up to 2 months of age. Sulfonamides compete for bilirubin binding sites on plasma albumin, increasing the risk of kernicterus in the newborn. Also, because the acetyltransferase system is not fully developed in the newborn, increased blood concentrations of the free sulfonamide can further increase the risk of kernicterus. /Sulfonamides/Elderly patients may be at increased risk of severe side/adverse effects. Severe skin reactions, generalized bone marrow depression, and decreased platelet count (with or without purpura) are the most frequently reported severe side/adverse effects in the elderly. An increased incidence of thrombocytopenia with purpura has been reported in elderly patients who are receiving diuretics, primarily thiazides, concurrently with sulfamethoxazole. The potential for these problems should also be considered for elderly patients taking other sulfonamide medications. /Sulfonamides/
Antidote and Emergency TreatmentMaintain an open airway and assist ventilation if necessary. Treat coma, seizures, hypotension, anaphylaxis, and hemolysis if they occur. Replace fluid losses resulting from gastroenteritis with intravenous crystalloids. Maintain steady urine flow with fluids to alleviate crystalluria ... Administer activated charcoal orally if conditions are appropriate. Gastric lavage is not necessary after small to moderate ingestions if activated charcoal can be given promptly. Most antibiotics are excreted unchanged in the urine, so maintenance of adequate urine flow is important. The role of forced diuresis is unclear. Hemodialysis is not usually indicated, except perhaps in patients with renal dysfunction and a high level of a toxic agent. /Antibacterial agents/
Gefahrstoffdaten17784-12-2(Hazardous Substances Data)